Recombinant human follicle-stimulating hormone and human chorionic gonadotropin for induction of spermatogenesis in a hypogonadotropic male.

Kliesch S, Behre HM, Nieschlag E

Fertility and sterility1 Jun 1995Cited by 48 (Europe PMC)

PMID7750608DOI10.1016/s0015-0282(16)57619-5PepBankPUB-07750608

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking hCG (human chorionic gonadotropin).

01HumanNot a test of hCG (human chorionic gonadotropin) aloneCase report or seriesEfficacy outcome
In a hypogonadal man with pituitary insufficiency, FSH with hCG produced first sperm in the ejaculate after 18 weeks.
In plain wordsIn a hypogonadal man, sperm first appeared after 18 weeks of FSH with hCG treatment.
Peptide
hCG (human chorionic gonadotropin)
Outcome
IncreaseFirst sperm appearance
Study
n = 1
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Time to first sperm in ejaculate
18 weeks
after start of FSH with hCG treatment, one hypogonadal man
Source sentences
Summary
After 18 weeks of treatment, first sperm were seen in the ejaculate and reached normal sperm concentrations after 24 weeks of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
A 44-year-old hypogonadal man with postpubertal pituitary insufficiency due to surgical removal of a prolactinoma.
Summary · context
Recombinant FSH (150 IU three times weekly) was administered together with hCG (1,500 IU twice weekly).
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0775060801
02HumanNot a test of hCG (human chorionic gonadotropin) aloneCase report or seriesEfficacy outcome
In a hypogonadal man with pituitary insufficiency, sperm concentration reached normal levels after 24 weeks of FSH with hCG.
In plain wordsIn a hypogonadal man, sperm concentration reached normal levels after 24 weeks of FSH with hCG.
Peptide
hCG (human chorionic gonadotropin)
Outcome
IncreaseNormal sperm concentration
Study
n = 1
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Time to normal sperm concentration
24 weeks
after start of FSH with hCG treatment, one hypogonadal man
Source sentences
Summary
After 18 weeks of treatment, first sperm were seen in the ejaculate and reached normal sperm concentrations after 24 weeks of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
A 44-year-old hypogonadal man with postpubertal pituitary insufficiency due to surgical removal of a prolactinoma.
Summary · context
Recombinant FSH (150 IU three times weekly) was administered together with hCG (1,500 IU twice weekly).
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0775060802
03HumanNot a test of hCG (human chorionic gonadotropin) aloneCase report or seriesEfficacy outcome
In a hypogonadal man with pituitary insufficiency, serum hormone levels were normal during FSH with hCG treatment.
In plain wordsIn a hypogonadal man, serum hormone levels were normal during FSH with hCG treatment.
Peptide
hCG (human chorionic gonadotropin)
Outcome
Not applicableSerum hormone levels
Study
n = 1
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Serum hormone levels were in the normal range and testicular volume increased.
2 context sentences(design, population, supporting numbers)
Summary · context
A 44-year-old hypogonadal man with postpubertal pituitary insufficiency due to surgical removal of a prolactinoma.
Summary · context
Recombinant FSH (150 IU three times weekly) was administered together with hCG (1,500 IU twice weekly).
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0775060803
04HumanNot a test of hCG (human chorionic gonadotropin) aloneCase report or seriesEfficacy outcome
In a hypogonadal man with pituitary insufficiency, testicular volume increased during FSH with hCG treatment.
In plain wordsIn a hypogonadal man, testicular volume increased during FSH with hCG treatment.
Peptide
hCG (human chorionic gonadotropin)
Outcome
IncreaseTesticular volume
Study
n = 1
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Serum hormone levels were in the normal range and testicular volume increased.
2 context sentences(design, population, supporting numbers)
Summary · context
A 44-year-old hypogonadal man with postpubertal pituitary insufficiency due to surgical removal of a prolactinoma.
Summary · context
Recombinant FSH (150 IU three times weekly) was administered together with hCG (1,500 IU twice weekly).
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0775060804
05HumanNot a test of hCG (human chorionic gonadotropin) aloneCase report or seriesSafety outcome
In a hypogonadal man with pituitary insufficiency, no adverse side effects occurred during FSH with hCG treatment.
In plain wordsIn a hypogonadal man, no adverse side effects occurred during FSH with hCG treatment.
Peptide
hCG (human chorionic gonadotropin)
Outcome
Not applicableAdverse side effects
Study
n = 1
Outcome group
Adverse events · Whole body
Source sentences
Summary
No adverse side effects were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
A 44-year-old hypogonadal man with postpubertal pituitary insufficiency due to surgical removal of a prolactinoma.
Summary · context
Recombinant FSH (150 IU three times weekly) was administered together with hCG (1,500 IU twice weekly).
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-0775060805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.